STATegics, Inc. is a South San Francisco-based company dedicated to the discovery and development of groundbreaking treatments for rare neurodegenerative diseases. With a focus on targeting the tissue-protective cytokine receptor, they have successfully identified innovative small molecules to address the underlying cause of Friedreich's ataxia (FA), a life-threatening neuromuscular disease currently lacking any treatment.
By addressing critical drivers in FA, STATegics' molecules also hold the potential to provide therapeutic solutions for various neuromuscular and neurodegenerative diseases, making them a promising player in the field of medical research and development.
Generated from the website